Merrimack Pharmaceuticals Stock Forecast, Price & News

Wall Street analysts have given Merrimack Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merrimack Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Merrimack Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Merrimack Pharmaceuticals.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.92) by $0.14.
View Merrimack Pharmaceuticals' earnings history.

Merrimack Pharmaceuticals' stock was trading at $2.76 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MACK stock has increased by 125.4% and is now trading at $6.22.
View which stocks have been most impacted by COVID-19.

Merrimack Pharmaceuticals shares reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Some companies that are related to Merrimack Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of MACK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MACK stock can currently be purchased for approximately $6.22.

Merrimack Pharmaceuticals has a market capitalization of $83.41 million.

Merrimack Pharmaceuticals employs 27 workers across the globe.

The official website for Merrimack Pharmaceuticals is www.merrimackpharma.com.

Merrimack Pharmaceuticals is headquartered at ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142.

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]